Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Aptorum Group Ltd Class A

Healthcare US APM

1.09USD
0.11(11.68%)

Last update at 2026-06-03T20:28:00Z

Day Range

0.931.10
LowHigh

52 Week Range

0.654.47
LowHigh

Fundamentals

  • Previous Close 0.98
  • Market Cap7.25M
  • Volume111626
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.56248M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00525M
  • Diluted EPS TTM-0.19

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1.37643M -4.15800M -4.34100M -11.52510M -27.11429M
Minority interest 0.01M -0.11007M 1.52M 1.73M 2.07M
Net income -1.36327M -4.26800M -2.82500M -5.31444M -25.28834M
Selling general administrative 1.64M 1.46M 4.37M 7.87M 7.70M
Selling and marketing expenses - - 0.05M 0.10M 0.10M
Gross profit 0.00000M -0.25500M 0.01M 0.08M 0.08M
Reconciled depreciation 0.00000M 0.31M 1.13M 1.21M 1.19M
Ebit - -4.01105M -10.60124M -22.96303M -19.06109M
Ebitda -1.81753M -3.75600M -9.47624M -21.75552M -17.86851M
Depreciation and amortization - 0.26M 1.12M 1.21M 1.19M
Non operating income net other - - - - -
Operating income -1.81753M -3.79600M -10.60100M -22.96303M -19.06109M
Other operating expenses 1.82M 3.80M 11.03M 18.81M 20.75M
Interest expense 0.10M 0.15M 0.12M 0.15M 0.09M
Tax provision - - - - -
Interest income - - - 0.15M -
Net interest income -0.09571M -0.14692M -0.12115M 0.15M -0.09360M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -1.51633M -6.21066M -1.82596M
Total revenue 0.00000M 0.00000M 0.43M 1.30M 1.54M
Total operating expenses 1.82M 3.54M 10.61M 17.59M 19.29M
Cost of revenue 0.00000M 0.26M 0.42M 1.22M 1.46M
Total other income expense net 0.44M -0.36100M 6.26M 11.44M -8.05321M
Discontinued operations - - - - -
Net income from continuing ops -1.37643M -4.15774M -4.34098M -11.52510M -27.11429M
Net income applicable to common shares - - - - -25.04839M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 18.69M 16.13M 20.64M 20.87M 21.91M
Intangible assets - - 0.15M 0.75M 0.88M
Earning assets - - - - -
Other current assets 0.14M 0.08M 0.40M 4.88M 0.65M
Total liab 4.90M 4.35M 5.26M 13.03M 4.40M
Total stockholder equity 23.12M 21.13M 24.85M 15.71M 23.61M
Deferred long term liab - - - - -
Other current liab 1.07M 1.00M 1.89M 6.18M 4.18M
Common stock 0.00008M 0.00006M 0.00005M 35.71M 35.64M
Capital stock 0.00008M 0.00006M 0.00005M 35.71M 35.64M
Retained earnings -73.79280M -72.42953M -68.16172M -65.33707M -55.53751M
Other liab - - - - -
Good will - - - - -
Other assets - - - - 0.30M
Cash 3.45M 0.87M 2.01M 1.88M 8.13M
Cash and equivalents - - - - -
Total current liabilities 4.59M 4.34M 2.10M 12.50M 4.38M
Current deferred revenue - - - - -
Net debt 0.07M 2.48M 1.36M 4.97M -7.91405M
Short term debt 3.52M 3.34M 0.20M 6.32M 0.19M
Short long term debt 3.42M 3.24M - 6.01M -
Short long term debt total 3.52M 3.35M 3.36M 6.85M 0.22M
Other stockholder equity 97.00M 93.47M 93.02M 45.31M 43.51M
Property plant equipment - - - - 3.89M
Total current assets 3.59M 0.96M 2.48M 7.07M 12.69M
Long term investments 15.10M 15.10M 16.10M 9.74M 4.16M
Net tangible assets - - - - 22.73M
Short term investments - - 0.00000M 0.10M 0.24M
Net receivables - 0.00455M 0.07M 1.41M 3.63M
Long term debt - - 3.06M 0.50M -
Inventory - - 0.00000M 0.03M 0.04M
Accounts payable - - - - 4.17M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.09231M 0.09M -0.01062M 0.03M -0.00202M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.07M 0.07M 0.13M 0.15M
Deferred long term asset charges - - - - -
Non current assets total 15.10M 15.17M 18.16M 13.80M 9.22M
Capital lease obligations 0.02M 0.12M 0.22M 0.34M 0.22M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00000M 0.06M 0.62M 2.44M 20.12M
Change to liabilities - - - - 0.86M
Total cashflows from investing activities - 0.06M 0.62M - 16.51M
Net borrowings 0.00000M 0.00000M 2.50M - -2.04351M
Total cash from financing activities 4.41M 0.00143M 4.09M 6.63M 2.78M
Change to operating activities - - - - 0.18M
Net income -1.36327M -4.26781M -4.34098M -11.52510M -27.11429M
Change in cash 2.58M -1.13111M -3.00753M -3.24861M 4.64M
Begin period cash flow 0.87M 2.01M 5.01M 8.26M 3.63M
End period cash flow 3.45M 0.87M 2.01M 5.01M 8.26M
Total cash from operating activities -1.83608M -1.19116M -7.72436M -12.31897M -14.65163M
Issuance of capital stock 5.07M 0.00000M 1.58M 0.00536M 4.00M
Depreciation 0.00000M 0.26M 1.13M 1.21M 1.19M
Other cashflows from investing activities - - 0.52M - -3.35809M
Dividends paid - - - - -
Change to inventory 0.00000M 0.00000M 0.01M 0.00805M 0.00336M
Change to account receivables 0.00000M 0.04M 0.42M -0.09570M -0.01650M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - -0.03802M 6.67M 4.32M
Change to netincome - - - - 8.19M
Capital expenditures 0.00000M 0.00000M 0.00301M 0.19M 0.14M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.10284M -0.21110M 0.41M 1.40M 1.02M
Stock based compensation 0.00000M 0.00000M 1.27M 1.65M 1.68M
Other non cash items -0.36997M 3.03M -6.18090M -5.04629M 0.61M
Free cash flow -1.83608M -1.19116M -7.72738M -12.50588M -14.78941M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
APM
Aptorum Group Ltd Class A		 0.11 11.68% 1.09 - - 23.35 0.32 31.22 -0.4545
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Aptorum Group Ltd Class A

17 Hanover Square, London, United Kingdom, W1S 1BN

Key Executives

Name Title Year Born
Mr. Darren Lui CEO, Chief Accounting Officer & Exec. Director 1982
Mr. Chung Yuen Huen Founder & Non-Exec. Director 1981
Dr. Clark Cheng Chief Medical Officer & Exec. Director 1980
Dr. Wai Yip Lee Head of R&D 1974
Mr. Martin Siu Head of Fin. NA
Mr. Chung Yuen Huen Founder, CEO & Non-Executive Director 1980
Mr. Martin Siu Head of Finance 1979
Mr. Kwok Kuen Wong Head of Finance 1956
Mr. Chung Yuen Huen Founder, CEO & Executive Director 1980
Mr. Kwok Kuen Wong Head of Finance 1956

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions